CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tonira Pharma Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tonira Pharma Limited
Plot No.23-24, G.I.D.C Estate
Nandesari
Phone: 91-265-2840795/28415p:91-265-2840795/28415 Vadodara, Gujarat  391340  India Ticker: 530155530155
This company was Merged or Acquired on 5/16/2012.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Tonira Pharma Limited is engaged in manufacturing and marketing of active pharmaceutical ingredients (APIs). The Company’s manufacturing units are situated at Nandesari and Ankleshwar. The Company is manufacturing bulk drugs, drugs intermediate, fine chemicals and others. The installed capacity varies with change in products, product mix. During the fiscal year ended March 31, 2011, the Company produced 58698.08 kilograms of bulk drugs and intermediates. The products manufactured by the Company include Aceclofenac, Benzarone, Benzbromarone, Benziodarone, Beventolol Hcl, Ebastine, Famotidine USP/EP/BP/JP, Glimepiride, Loratadine, Mefenamic Acid, Nifedipine IP/BP/USP/EP, Protryptilline HCL, Quetiapine Fumarate, Sodium Alendronate, Tamsulosin HCL, Tramadol HCL, Zaltoprofen and Zolpidem Tartrate EP/BP. As on August 2010, products, such as Tamsulosin HCL, Mosapride citrate Dihydrate and Zonisamide were under development. In May 2012, the Company merged with Ipca Laboratories Ltd.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20113/31/2011Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Non-Independent Chairman of the Board Bhailalbhai B.Shah 65 3/26/2009 8/13/1992
Compliance Officer, Company Secretary HetaMehta
Additional Executive Director Lalit K.Gupta 61 3/23/2011 3/23/2011
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 151 (As of 3/31/2011)
Outstanding Shares: 7,944,200 (As of 3/31/2012)
Shareholders: 9,452
Stock Exchange: BOM
Fax Number: 91-265-2840868


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023